ASSENT I-TIMI 10C

OBJECTIVE: To compare the safety of several doses of TNK-tPA with rtPA for the treatment of ST elevation myocardial infarction.

View/Download
_______________________________________________________________________________

1. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Van de Werf F, Cannon CP, Luyten A, et al. Am Heart J 1999;137:786-91.
   | Abstract | Request Reprints |
   

2. Rates of serious bleeding requiring transfusion in AMI patients treated with TNK-tPA. Fox NL, Cannon CP, Berioli S, Wang-Clow F, Danays T, Sarelin H, Braunwald E, Van de Werf F. J Am Coll Cardiol 1999;33(Suppl A):353A.
   | Request Reprints |
   
   
3. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.Wang-Clow F, Fox NL, Cannon CP, et al. Am Heart J 2001;141:33-40.
   | Abstract | Request Reprints |